That seems odd that another company has to pay for a failure of another, especially if the procedure isn't recognised in a trial. But i don't know, so thanks for clarifying for me.
Ann: Exceptional Results in Second Valve-in-Valve Case, page-36
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |